Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The 14th European Multiple Myeloma Academy (EMMA) will be held in Madrid, Spain from 16-17 September, 2016. The program covers basic and clinical multiple myeloma research and consists of a mix between formal presentations, workshops and round table discussions.

EMMA 2016

16–17 September 2016 | Madrid, Spain

EMMA 2016

16–17 September 2016 | Madrid, Spain

The 14th European Multiple Myeloma Academy (EMMA) will be held in Madrid, Spain from 16-17 September, 2016. The program covers basic and clinical multiple myeloma research and consists of a mix between formal presentations, workshops and round table discussions.

What are the biggest challenges associated with treating MGUS? 1:06
What are the biggest challenges associated with treating MGUS?
Niels van de Donk • 16 Sep 2016
How to manage monoclonal gammopathy of undetermined significance (MGUS) 2:02
How to manage monoclonal gammopathy of undetermined significance (MGUS)
Niels van de Donk • 16 Sep 2016
Are we ready for mutational directed treatment: addressing the genomic basis of myeloma 10:07
Are we ready for mutational directed treatment: addressing the genomic basis of myeloma
Gareth Morgan et al. • 16 Sep 2016
Highlights from the 2016 European Multiple Myeloma Academy (EMMA) and overview of EMMA 2017 1:24
Highlights from the 2016 European Multiple Myeloma Academy (EMMA) and overview of EMMA 2017
Jesús San Miguel • 16 Sep 2016
Frontline treatment of elderly multiple myeloma patients and management of relapse/refractory 11:22
Frontline treatment of elderly multiple myeloma patients and management of relapse/refractory
Enrique Ocio et al. • 16 Sep 2016
An update on immunotherapy for multiple myeloma in 2016 16:05
An update on immunotherapy for multiple myeloma in 2016
Ignacio Bermejo et al. • 16 Sep 2016
Allogeneic transplant in multiple myeloma: who should receive it and the future of transplant 8:29
Allogeneic transplant in multiple myeloma: who should receive it and the future of transplant
Heinz Ludwig et al. • 16 Sep 2016
Changing the way we treat multiple myeloma based on biological markers in 2016 2:32
Changing the way we treat multiple myeloma based on biological markers in 2016
Paulo Lúcio • 16 Sep 2016
Frontline treatment for young multiple myeloma patients 11:38
Frontline treatment for young multiple myeloma patients
Gareth Morgan et al. • 16 Sep 2016
New tools for multiple myeloma treatment monitoring 15:38
New tools for multiple myeloma treatment monitoring
Bruno Paiva et al. • 16 Sep 2016
An overview of the format of the 2016 European Multiple Myeloma Academy (EMMA) by Prof. San Miguel 1:56
An overview of the format of the 2016 European Multiple Myeloma Academy (EMMA) by Prof. San Miguel
Jesús San Miguel • 16 Sep 2016
Overview and rationale for practical workshops at the 2016 European Multiple Myeloma Academy (EMMA) 2:11
Overview and rationale for practical workshops at the 2016 European Multiple Myeloma Academy (EMMA)
Jesús San Miguel • 16 Sep 2016
Managing challenging patients with Waldenström’s macroglobulinemia 1:22
Managing challenging patients with Waldenström’s macroglobulinemia
Stathis Kastritis • 16 Sep 2016
The challenges associated with managing multiple myeloma patients on immunotherapy 1:22
The challenges associated with managing multiple myeloma patients on immunotherapy
Ignacio Bermejo • 16 Sep 2016
What are the current treatment options for Waldenström’s macroglobulinemia? 1:26
What are the current treatment options for Waldenström’s macroglobulinemia?
Stathis Kastritis • 16 Sep 2016
The basis for immunotherapy in multiple myeloma 2:56
The basis for immunotherapy in multiple myeloma
Ignacio Bermejo • 16 Sep 2016
The content of VJHemOnc is intended for healthcare professionals